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Abstract
Background: Reactive astrocytes are implicated in the development and maintenance of neuroinflammation in the
demyelinating disease multiple sclerosis (MS). The sphingosine kinase 1 (SphK1)/sphingosine1-phosphate (S1P) receptor
signaling pathway is involved in modulation of the inflammatory response in many cell types, but the role of S1P receptor
subtype 3 (S1P3) signaling and SphK1 in activated rat astrocytes has not been defined.
Methodology/Principal Findings: Using immunohistochemistry we observed the upregulation of S1P3 and SphK1
expression on reactive astrocytes and SphK1 on macrophages in MS lesions. Increased mRNA and protein expression of S1P3
and SphK1, as measured by qPCR and Western blotting respectively, was observed after treatment of rat primary astrocyte
cultures with the pro-inflammatory stimulus lipopolysaccharide (LPS). Activation of SphK by LPS stimulation was confirmed
by SphK activity assay and was blocked by the use of the SphK inhibitor SKI (2-(p-hydroxyanilino)-4-(p-chlorphenyl) thiazole.
Treatment of astrocytes with a selective S1P3 agonist led to increased phosphorylation of extracellular signal-regulated
kinase (ERK)-1/2), which was further elevated with a LPS pre-challenge, suggesting that S1P3 upregulation can lead to
increased functionality. Moreover, astrocyte migration in a scratch assay was induced by S1P and LPS and this LPS-induced
migration was sensitive to inhibition of SphK1, and independent of cell proliferation. In addition, S1P induced secretion of
the potentially neuroprotective chemokine CXCL1, which was increased when astrocytes were pre-challenged with LPS. A
more prominent role of S1P3 signaling compared to S1P1 signaling was demonstrated by the use of selective S1P3 or S1P1
agonists.
Conclusion/Significance: In summary, our data demonstrate that the SphK1/S1P3 signaling axis is upregulated when
astrocytes are activated by LPS. This signaling pathway appears to play a role in the establishment and maintenance of
astrocyte activation. Upregulation of the pathway in MS may be detrimental, e.g. through enhancing astrogliosis, or
beneficial through increased remyelination via CXCL1.
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Introduction
Astrocytes are the most abundant glial cells in the mammalian
central nervous system (CNS). They have important functions in
maintenance of homeostasis and are involved in synaptic function
and physical structuring of the CNS during development [1], and
become reactive in response to pathological insults [2,3]. They
can upregulate genes involved in amplification of inflammation
by attracting inflammatory cells to specific sites and limit immune
cell invasion of adjacent healthy parenchyma [4,5]. In inflam-
matory demyelinating multiple sclerosis (MS) lesions, reactive
astrocytes present a hypertrophic phenotype and form astroglial
scars.
Astrocytes can be activated in vitro by various stimuli such as
LPS, a bacterial polysaccharide commonly used as a pro-
inflammatory stimulus which signals mainly through the Toll-like
receptor (TLR) 4. LPS activates the sphingosine kinase 1/
sphingosine-1-phosphate (SphK1/S1P) signaling axis in other cell
types including microglia [6] and macrophages [7], leading to
translocation of SphK1 to the plasma membrane where it converts
its substrate sphingosine to the bioactive sphingolipid S1P [8–10].
S1P can elicit a wide variety of cellular responses including
inflammation and can act intracellularly as a second messenger or
extracellularly by binding to the G protein-coupled receptors S1P1
to S1P5 [11,12]. In the CNS, S1P is involved in induction of
astrocyte proliferation, migration and survival [13], and was found
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suggesting its involvement in chronic neuroinflammation [14].
SphK1 CNS expression is increased by kainic acid or hypoxia
[15,16], and probably results in increased production of S1P.
However, the expression of SphK1 in MS CNS tissues has not
been reported.
All S1P receptors except S1P4 are expressed in the CNS as
assessed at the mRNA level. In experimental autoimmune
encephalomyelitis (EAE), an animal model commonly used to
study inflammatory aspects of MS, S1P receptors were shown to
be differentially regulated as S1P1 and S1P5 mRNAs were
downregulated at days 11 and 29 in spinal cord, whereas S1P4
and S1P3 mRNAs were upregulated [17]. The increase of S1P4
expression probably resulted from infiltration of immune cells.
The S1P3 receptor is expressed by several CNS cell types including
astrocytes, microglia and neurons, and by immune cells such as
dendritic cells and B lymphocytes [18,19]. The increased
expression of this receptor during EAE could therefore be due
either to immune cell infiltration or upregulation by CNS cells, or
both. In normal CNS tissues, astrocytes were reported to express
mainly S1P3 and S1P1 mRNA, with very low levels of S1P2 and
S1P5 [20–22].
FTY720 is a S1P analogue that has recently been approved as
an anti-inflammatory therapy for MS. It is a pro-drug that needs
to be phosphorylated to FTY720P by sphingosine kinase 2
(SphK2) to become active and act as agonist of S1P1, 3, 4 and 5
receptors [23,24]. It decreases immune cell trafficking by
activating S1P1 on lymphocytes, thereby inducing internalization
and degradation of these receptors [25–27], which in consequence
leads to sequestration of the lymphocytes in lymph nodes by
preventing them from following the S1P gradient that would guide
them into the bloodstream [28]. The resulting lymphopenia
decreases the migration of immune cells into the CNS. FTY720
readily crosses the blood-brain barrier [29], and it may exert
additional effects in the CNS which would probably be mediated
via S1P1, S1P3 and S1P5, although there is no strong evidence
demonstrating direct neuroprotective effects.
Until recently the expression of S1P3 on astrocytes in vitro or in
neuroinflammatory disorders and the roles of this signaling axis in
CNS inflammation had not been investigated, but van Doorn and
colleagues [30] have demonstrated S1P3 upregulation in MS
tissues.
In the present study, we have confirmed this observation and
shown for the first time the enhanced expression of SphK1 on
Figure 1. S1P3 and SphK1 are upregulated in MS lesions. (A, B): Immunohistochemical peroxidise staining shows that S1P3 receptor and
SphK1 enzyme expressions are increased in a chronic-active MS lesion which was located in parietal subventricular white matter. S1P3 expression is
strong on reactive astrocytes in this lesion border (C), in the lesion (D) and on perivascular cells (G), but is weak in normal control brain white matter
(H). SphK1 expression is increased in reactive astrocytes (E) and in macrophages in this MS lesion (F). A particularly high expression of SphK1 is seen in
perivascular inflammatory cells (I), whereas its expression is very low in normal control brain white matter (J). This Figure shows representative
stainings. Scale bars are 200 mm for A and B, and 20 mm for C–J. The sections were counterstained with haematoxylin.
doi:10.1371/journal.pone.0023905.g001
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showed increased expression and functionality of both SphK1 and
S1P3 in cultures of activated rat astrocytes, which demonstrated
the potential therapeutic impact of targeting this signaling axis in
MS.
Results
S1P3 and SphK1 are expressed on reactive astrocytes in
MS lesions
Eight MS lesions from seven patients, and scored as actively
demyelinating, chronic-active or chronic-inactive were analyzed
by immunohistochemistry. Expression of the receptor S1P3 was
especially strong on reactive astrocytes in plaques and their lesion
borders (Fig. 1A, C, D). Expression of S1P3 was also detected in
perivascular inflammatory cells in cuffs within plaques and also in
surrounding tissue (Fig. 1G). In comparison, only weak expression
of S1P3 was detected in normal control brain (Fig. 1H). Co-
expression of S1P3 and glial fibrillary acidic protein (GFAP) on all
reactive astrocytes in MS lesions and surrounding tissues was
confirmed by double-immunostaining (Fig. 2A), but only small
numbers of S1P3-expressing CD68-positive macrophages could
also be detected (data not shown).
We also found an increased expression of SphK1 in MS lesions
(Fig. 1B), with only very weak expression of the enzyme in normal
control brain (Fig. 1J). This increase was particularly marked on
cells with a macrophage-like morphology in plaques and their
borders (Fig. 1F). Expression of SphK1 was also increased on
reactive astrocytes (Fig. 1E) in the same areas, and in perivascular
inflammatory cell cuffs (Fig. 1I). Co-expression of SphK1 and
GFAP on reactive astrocytes in MS lesions and their borders was
confirmed by double immunostaining (Fig. 2B), and SphK1
expression on macrophages in MS lesions, lesion borders and
around blood vessels was confirmed by double immunostaining for
SphK1 and CD68 (Fig. 2C, D).
S1P3 and SphK1 mRNA and protein are increased in
activated astrocytes in vitro
To test whether the upregulation of S1P3 receptor and the
enzyme SphK1 observed in MS lesions can be induced in vitro
under pro-inflammatory conditions, primary rat astrocytes were
activated with the pro-inflammatory stimulus LPS (100 ng/ml) for
5 h and 24 h. This concentration of LPS was found to induce
maximal response of the astrocytes (data not shown). The mRNA
level of S1P3 was significantly upregulated after a 5 h incubation
with LPS (3-fold) compared to untreated cells (Fig. 3B), and
SphK1 was upregulated by 10-fold (Fig. 3C). At 24 h post-
stimulation, expression of S1P3 and SphK1 was back to basal level.
Neither S1P1 nor SphK2 were regulated by the LPS (Fig. 3A, D).
The increase of S1P3 and SphK1 was confirmed at the protein
Figure 2. S1P3 and SphK1 are expressed by reactive astrocytes and macrophages in MS lesions. Immunofluorescence co-localization
studies confirmed that S1P3 is predominately expressed by reactive astrocytes (A). SphK1 is also expressed on reactive astrocytes (B), but the major
cell type expressing SphK1 is macrophage in lesions and perivascular cuffs (C–D). Scale bars are 10 mm.
doi:10.1371/journal.pone.0023905.g002
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incubated in culture medium for 5 or 24 h with LPS (100 ng/ml). The mRNA levels of S1P1 (A), S1P3 (B), SphK1 (C) and SphK2 (D) were assessed after
5 h and 24 h incubation. Quantitative PCR results are shown as the percentage expression of HKG (GAPDH) and represent mean 6 SEM of three
independent experiments. LPS mediated sustained upregulation of S1P3 (E–F) and SphK1 (G–H) as shown by Western blots of plasma membrane
fractions. Primary rat astrocytes were incubated with LPS (100 ng/ml) in serum-free medium containing 0.25% BSA for 12 and 48 h. Representative
immunoblots are shown. Graphs represent the mean 6 SEM of three independent experiments and are reported as protein expression normalized to
actin, expressed as fold change over basal level. One-Way ANOVA followed by Bonferroni’s multiple comparison test: *p,0.05, **p,0.01 vs.
respective control.
doi:10.1371/journal.pone.0023905.g003
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S1P3 receptor and SphK1 were upregulated on astrocyte plasma
membranes in response to LPS challenge after a 12 h treatment
(Fig. 3E, G), which was maintained for at least 48 h (Fig. 3F, H).
LPS induces SphK1 activity and increases S1P3 receptor
signaling
The upregulation of SphK1 on plasma membranes indicates
that the enzyme was translocated and thus activated in response to
stimulation with LPS. This was confirmed by thin layer
chromatography, using extracts of serum-deprived cells stimulated
or not with LPS (100 ng/ml) for 30 min. SphK1 activity was
significantly increased in LPS-stimulated astrocytes, and pre-
incubation with SKI (10 mg/ml), described as a selective SphK1
inhibitor [31], reversed the activity of the enzyme to the basal level
(Fig. 4A).
Phosphorylation of ERK-1/2 and Akt, two signaling pathways
downstream of S1P receptors, was then assessed following
stimulation with the S1P3 specific agonist Compound 20, a
dicyclohexylamide molecule which showed an agonistic activity on
S1P3 (EC50=350 nM), while not activating any other S1P
receptor (EC50s.40 mM) [32]. Primary rat astrocytes were pre-
incubated with 100 ng/ml LPS for 12 h in serum-free medium
and then stimulated with the S1P3 agonist (Compound 20, 10 mM)
for 20 min. LPS treatment alone for 12 h did not affect ERK-1/2
phosphorylation compared to untreated controls (Fig. 5A).
Stimulation with the S1P3 agonist (Compound 20), increased
ERK-1/2 phosphorylation by two-fold in cells not treated with
LPS and was further elevated in cells pre-challenged with LPS.
Phosphorylation of Akt was also induced by treatment with the
S1P3 agonist, but statistical significance was not reached (Fig. 5B).
However, in the case of pre-activation with LPS, very little or no
elevation of Akt phosphorylation was observed with the S1P3
agonist when compared to the non-activated cells.
In contrast, when using the specific S1P1 receptor agonist
AUY954, no further increase in ERK-1/2- or Akt-phosphoryla-
tion levels was observed in LPS-stimulated cells compared to the
phosphorylation mediated by the agonist alone (Fig. 5C, D).
Involvement of SphK1 activity in LPS-induced astrocyte
migration
Because of the potential role of ERK signaling in cell migration,
a scratch assay was then performed to investigate the role of LPS-
induced activation in the migratory behaviour of astrocytes in
response to S1P. Astrocytes were allowed to migrate for 48 h after
treatment with LPS (100 ng/ml), S1P (500 nM) or a combination
of both in a scratch assay. Treatments were repeated after 24 h
without changing the medium. As shown in Figure 6, all
treatments significantly increased migration of astrocytes into the
scratches when compared to untreated cells (Fig. 6A). When LPS
and S1P were combined, astrocyte migration was not significantly
increased compared to migration induced by LPS or S1P alone
(Fig. 6D).
Long-term treatment with the S1P3 agonist (Compound 20)
caused cells to detach, thus the role of the S1P3 receptor in
astrocyte migration in LPS-stimulated astrocytes could not be
assessed directly. We instead investigated whether LPS-induced
migration depends directly on SphK1 activity. Cells were pre-
incubated with SKI (10 mg/ml) 1 h before performing the
scratches, followed by treatment with LPS (100 ng/ml) and they
were then allowed to migrate for 48 h. Pre-incubation with SKI
significantly inhibited LPS-induced migration of astrocytes
(Fig. 7C) whilst not affecting cell survival, as assessed by visual
observation and lack of LDH release in the supernatants (data not
shown).
S1P was previously reported to be mitotic [33], and ERK
signaling is involved in cell proliferation. Therefore we investigated
if this was also the case in our cultures by stimulating the cells for
24 hours with increasing concentrations of S1P or LPS in the
presence of [
3H]-thymidine. Figure 7A shows the dose-dependent
increase in astrocyte proliferation in response to S1P. In contrast
LPS has no effect on astrocyte proliferation (Fig. 7B).
In order to define if the S1P-induced astrocyte migration
depends on proliferation, the scratch migration assay was repeated
as before, but in presence or absence of an antimitotic agent
(Cytosine b-D-arabinofuranoside hydrochloride, 10 mM) (Fig. 7
D). Data show that the astrocyte migration in the control wells was
partially dependent on proliferation, as cells cover less area of the
scratch in the presence of the antimitotic factor. Similarly, S1P-
induced migration was also strongly dependent on astrocyte
proliferation and significantly reduced in the presence of the
antimitotic factor compared to S1P alone. In contrast, the
migration induced by LPS did not depend significantly on
proliferation as there was no significant difference between cells
treated with LPS, or with LPS and the antimitotic factor.
LPS and S1P induce CXCL1 release
The release of cytokines and chemokines was shown to be
induced by stimulation with S1P in different cell types [6,34]. In
order to better define the link between TLRs and the SphK1/S1P
axis, cytokines and chemokines produced by astrocytes in response
to stimulation with LPS (10 ng/ml, 100 ng/ml, 1 mg/ml) or S1P
(100 nM, 1 mM, 5 mM) were analyzed by a Multiplex ELISA for a
total of 23 different factors. Following 24 h stimulation, CXCL1
was shown to be the factor most induced by both stimuli (data not
shown). Other factors induced by both stimuli were RANTES and
monocyte chemoattractant protein-1 (MCP-1), but to a lesser
extent (data not shown).
Because CXCL1 has potential neuroprotective effects on
oligodendrocytes, we chose to focus the next experiments on the
regulation of its release through S1P1 or S1P3 receptors, following
pre-activation with LPS. Astrocytes were treated or not with LPS
(100 ng/ml) for 12 h, followed by stimulation with S1P (1 mM),
Figure 4. SphK1 is activated in response to LPS. Serum-deprived
astrocytes were incubated for 30 min with 100 ng/ml LPS in the
presence or absence of SKI (10 mg/ml). 100 mg of cell extracts were used
to determine SphK1 activity by thin layer chromatography. Data
represents the mean 6 SEM of three independent experiments. One-
Way ANOVA followed by Bonferroni’s multiple comparison test:
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0023905.g004
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AUY954 (10 mM) in fresh medium for another 5-hour period.
CXCL1 released into the supernatant was then measured by
ELISA. Cells pre-treated with LPS for 12 h followed by medium
replacement showed increased CXCL1 release without any
further activation, indicating that LPS-induced activation lasts
for several hours (Fig. 8). When S1P was given after pre-
stimulation with LPS, CXCL1 release was further increased by 3-
fold. Furthermore, although no induction of CXCL1 in response
to the S1P3 agonist was measured in non-activated cells, CXCL1
release was induced by the S1P3 agonist in cells pre-treated with
LPS. In contrast to the S1P3 agonist, AUY954 did not further
increase CXCL1 release induced by LPS challenge itself. These
data demonstrate that the LPS-induced increase of S1P3 receptor
leads to increased functionality, as CXCL1 release induced by S1P
in activated astrocytes is mediated mainly via the S1P3 rather than
the S1P1 receptor.
Discussion
We confirmed in this study an increased expression of the S1P3
receptor on reactive astrocytes in actively demyelinating and
chronic-inactive MS lesions, as described recently [30]. In
addition, we showed for the first time that the enzyme SphK1 is
strongly upregulated in macrophages, but also on reactive
astrocytes in both types of MS lesion. Furthermore, both S1P3
Figure 5. Increased S1P3-mediated ERK-1/2, but not Akt signaling by LPS. Astrocytes were serum-deprived during the 12 h treatment with
LPS and were then stimulated for 20 min with 10 mM S1P3 agonist (Compound 20) or 1 mM AUY954. The results show the relative ERK-1/2
phosphorylation (A, C ) and Akt phosphorylation (B, D) 6 SEM normalized against actin for three (A, B) and two (C, D) independent experiments. One-
Way ANOVA followed by Bonferroni’s multiple comparison test: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0023905.g005
Upregulation of SphK1/S1P3 in Activated Astrocytes
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23905and SphK1 expression was shown to be strongly expressed in
perivascular inflammatory cell cuffs in MS brain. In contrast, little
or no expression of SphK1 and S1P3 was seen in normal control
brain.
In MS, macrophages infiltrate the CNS parenchyma where they
contribute to tissue damage, release of pro-inflammatory media-
tors, impairment of BBB functions and also mediate damage and
phagocytosis of myelin, oligodendrocytes and axons. SphK1
activity was shown to drive macrophages towards a pro-
inflammatory phenotype, inducing the release of pro-inflammato-
ry stimuli which can cause further tissue damage [35]. Addition-
ally, SphK1 is upregulated by excitotoxicity and hypoxia in
astrocytes and glioma cells, respectively [15,16]. Both types of
injury probably contribute to neuronal damage in MS tissue [36],
and increased S1P production in the CNS could well be an
additional player in the neurodegenerative cascade by increasing
astrogliosis. Our finding of high SphK1 expression by infiltrating
macrophages and reactive astrocytes in MS lesions suggests that
inhibition of SphK1 activity may be beneficial in MS by
dampening macrophage- and astrocyte-mediated inflammation
and tissue damage. This is a potential additional benefit of the new
MS drug FTY720 as it was recently shown to inhibit SphK1 [37].
In agreement with the study by van Doorn et al. [30] S1P3 was
not substantially expressed on macrophages in MS lesions, and a
recent study showed that in human donor macrophages and
microglia S1P3 is expressed only at relatively low levels [37]. We
therefore chose to focus on the role of the SphK1/S1P3 axis in
activated astrocytes.
Upregulation of receptor S1P3 mRNA in CNS tissues was
previously demonstrated in EAE [17], although the identity of the
cells overexpressing S1P3 was not elucidated due to the lack of
specific antibodies against murine S1P3 for immunohistochemistry.
The upregulation of S1P3 receptors on astrocytes was previously
described in a mouse model of the neurodegenerative Sandhoff
disease, a prototypical lysosomal storage disorder [38,39]. It was
demonstrated that both S1P3 and SphK1 deficient mice had a
milder disease course with decreased proliferation of glial cells and
less pronounced astrogliosis, clearly indicating a role of the
SphK1/S1P3 axis in the neurodegenerative process [39]. Howev-
er, it remains to be shown if this is also the case in EAE. An
additional level of complexity in interpreting potential benefit of
FTY720 via S1P3 activation comes from the fact that the fate of
this receptor upon activation is not well understood, as it could
either be internalized and recycled or internalized and degraded.
The fate of the internalized receptor is important within the
context of FTY720, as it may determine whether the drug works as
an agonist or a functional antagonist [40].
In line with the increase of SphK1 and S1P3 expression on
reactive astrocytes in MS lesions, we showed in an in vitro system
using rat primary astrocyte cultures that SphK1 and S1P3 mRNA
and protein levels were upregulated when stimulated by LPS. S1P3
and SphK1 mRNAs were markedly upregulated five hours after
treatment. Interestingly, mRNA levels of S1P1 and SphK2 were
not modulated in rat astrocytes, thus differing from the study by
van Doorn et al. [30] where TNFa increased the mRNA both of
S1P1 and S1P3 in human astrocytes, thereby indicating potential
species differences. Alternatively, this difference could come from a
distinct effect of TNFa in comparison to LPS, but upregulation of
both S1P1 and S1P3 by LPS was described in human gingival
epithelial cells [41]. Astrocyte activation occurs through several
different pathways, thus TLR activation by LPS can certainly
drive different cellular responses other than those elicited other
pro-inflammatory stimuli, such as cytokines. The concomitant
regulation of SphK1 and S1P3 was demonstrated to play a role in
murine cardiac fibrosis [42] and in transdifferentiation of
myoblasts into myofibroblasts [43]. Furthermore, knocking down
SphK1 by siRNA led to reduced S1P3 mRNA expression in MCF-
7 Neo cells [44]. As a result, ERK-1/2 phosphorylation via S1P/
S1P3 was decreased, thereby abrogating establishment of the
migratory phenotype. An increased S1P3 and SphK1 expression
could conversely lead to an enhanced migratory phenotype. All
these data clearly indicate that SphK1 and S1P3 can be
functionally linked, and suggest the involvement of ERK signaling
in cell migration.
Various growth factors or pro-inflammatory stimuli [45]
including LPS [7] have been shown to activate SphK1, but we
show here for the first time that this is also the case in primary
astrocytes, as demonstrated by the increased expression of SphK1
protein at the plasma membrane fraction and further verified by
direct measurement of its activity.
Several laboratories have described signaling of S1P receptors in
astrocytes in vitro showing that S1P receptor stimulation by S1P
Figure 6. S1P and LPS induce astrocyte migration in a scratch
assay. Astrocytes were stimulated with S1P (500 nM), LPS (100 ng/ml)
or combined treatments of S1P+LPS. Cells were allowed to migrate into
the scratch for 48 h. The images show the representative migration of
astrocytes into a scratch in response to the different stimuli 48 h after
treatment (A–D). The surface of area covered by GFAP immunoreactivity
was plotted and each scratch was evaluated with an average of four
photographs, and each treatment group represented five to six
replicates (bar graph). Data are representative of at least three
independent experiments 6 SEM. One-Way ANOVA followed by
Dunnett’s post-test: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0023905.g006
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with cell proliferation or migration [44,46–48]. In addition,
Osinde et al. [49] showed that the S1P receptor agonist FTY720P
also induced phosphorylation of ERK-1/2 in astrocytes, which
was assumed to be predominantly mediated via S1P1 activation.
However, in their study, the S1P-mediated ERK-1/2 phosphor-
ylation was not inhibited by a S1P1 specific antagonist, but only by
a S1P1/S1P3 specific antagonist, indicating that S1P-mediated
ERK-1/2 phosphorylation occurred not only via S1P1 but also via
S1P3 receptors.
All aforementioned studies were performed under basal
conditions, i.e. without activation of astrocytes by pro-inflamma-
tory stimuli. To address the consequences of the upregulation of
S1P3 receptor by LPS, we used the selective S1P3 agonist
Compound 20 [32] to assess the magnitude of downstream
signaling. We demonstrated an increased S1P3-mediated ERK-1/
2 phosphorylation in LPS-treated rat astrocytes when compared to
non-activated cells. This enhanced phosphorylation was observed
only after stimulation of S1P3 and not of S1P1 (data not shown),
indicating that S1P3 signaling is preferentially increased in
astrocytes under pro-inflammatory conditions in vitro. This was
further supported by our data showing that LPS did not lead to an
increased expression of S1P1 receptor mRNA. Phosphorylation of
Figure 7. LPS-induced astrocyte migration is SphK1-dependent, but proliferation-independent. Astrocyte were treated with increasing
concentrations of S1P (10 nM, 100 nM, 1000 nM) (A) or LPS (1 ng/ml, 10 ng/ml, 100 ng/ml) (B), and cell proliferation was measured using a [
3H]-
thymidine uptake assay. Data are representative of three independent experiments 6 SEM. One-Way ANOVA followed by Dunnett’s post-test: (A)
*p,0.05 vs. control, ***p,0.001 vs. control. Astrocytes were pre-treated or not with SKI (10 mg/ml, 1 h) and then stimulated with LPS (100 ng/ml) (C)
or stimulated with S1P (500 nM) and LPS (100 ng/ml), respectively, in the presence or absence of 10 mM antimitotic treatment (D). The graphs show
the SKI-mediated inhibition of LPS-induced migration (C) and the influence of antimitiotic treatment on S1P- or LPS-induced migration after 48 h
incubation (D). The surface of area covered by GFAP immunoreactivity is plotted. Each scratch was evaluated with an average of four photographs,
and each treatment group represented five to six replicates. Data are representative of three independent experiments 6 SEM. One-Way ANOVA
followed by Dunnett’s post-test: (C) *p,0.05, **p,0.01; (D) *p,0.05 **p,0.01 vs. respective control.
doi:10.1371/journal.pone.0023905.g007
Figure 8. S1P3 contributes to the S1P-induced CXCL1 release
by primary astrocytes. Astrocytes were pre-treated with or without
LPS (100 ng/ml) for 12 h in serum-free medium and then stimulated or
not with S1P (1 mM), a S1P3 agonist (Compound 20, 10 mM) or a S1P1
agonist (AUY954, 10 mM) for 5 h. The graph shows the effect of LPS pre-
treatment on the release of CXCL1 by S1P, S1P3 or S1P1 agonists. Data
are a pool of two independent experiments each performed in six
replicates 6 SEM. One-Way ANOVA followed by Bonferroni’s multiple
comparison test: **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0023905.g008
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receptors, is associated with cell survival. The S1P3 receptor was
shown to mediate cytoprotective effects via Akt upregulation in
human endothelial cells in response to vascular endothelial growth
factor (VEGF) [50]. We show here the direct activation of Akt via
S1P3 activation in response to a S1P3 agonist, but the S1P3-
mediated Akt signaling was not further increased in LPS-activated
astrocytes, suggesting that out of the two investigated pathways,
ERK-1/2 is dominant over the Akt pathway in LPS-activated
astrocytes.
ERK-1/2 is an important player in migration or proliferation.
The SphK1/S1P axis has also been implicated in migratory
behaviour of different cell types, but some studies show that it has
a positive effect on migration [21,44], whereas others show that it
is inhibitory [51]. This may depend in part on which of the S1P
receptor is involved in signaling, as was suggested by a study which
showed that S1P1 was driving migration in endothelial cells,
whereas S1P2 was responsible for inhibition of migration [52].
In order to explore the role of the SphK1/S1P axis in the
migration of astrocytes, we performed a scratch assay, as described
by Mullershausen et al. [21], and found that both LPS and S1P
induced astrocyte migration, but LPS and S1P together did not
exhibit any additive effect. Migration in this assay could occur
through motility of the cells, but also through cell division. S1P has
been described previously as having a mitotic effect on astrocytes
through ERK activation [33], further suggesting a contribution of
proliferation to our migration assay. A direct proliferation assay
assessing
3H-thymidine incorporation confirmed that S1P induced
astrocyte proliferation, whereas LPS did not. The use of an
antimitotic factor in the scratch assay further showed that the LPS-
induced migration differs from the migration induced by
exogenous S1P, the latter being largely mediated through invasion
of the scratch by dividing cells, whereas this was not the case for
LPS. Because LPS-induced migration is prevented by inhibition of
SphK1, endogenous S1P is likely involved in the migration, but
not through proliferation. Long-term treatment with the S1P3
agonist caused cells to detach, thus we were not able to directly
assess the role of this receptor following LPS treatment.
The hypothesis of Long and colleagues [44] which suggests that
increased S1P3 and SphK1 expression can lead to enhanced
migration could thus not be verified for astrocytes, but a link
between both signaling pathways is nevertheless supported by our
observation that LPS-induced migration was dependent on SphK1
activity as demonstrated by the use of a SphK1 inhibitor. It is now
known that SphK1 can translocate to other compartments than
plasma membranes, suggesting that S1P is produced locally in
these compartments to act directly on intracellular targets [53,54],
independently of S1P receptors. Interestingly, a recent paper by
Berdyshew et al. [55] demonstrates that production of intracellular
S1P is essential to induce the motility of lung endothelial cells, even
though in their case it seemed to be through release of S1P and
signaling from outside the cells. We were not able to measure
extracellular levels of S1P in our culture system, thus it has not
been possible to assess whether LPS induced the release of S1P
through the increased activation of SphK1. However, because
exogenous S1P, at a relatively high concentration, was able to
induce proliferation, whereas LPS did not affect proliferation at
all, we would argue that the S1P produced through the LPS-
induced SphK1 activation signals differently than exogenous S1P,
and likely increased cell motility rather than proliferation, since
inhibition of SphK1 resulted in decreased LPS-induced migration
in which proliferation does not play a role.
S1P induces release of growth factors such as FGF-2 or GDNF
in astrocytes [56,57], which could act in a paracrine fashion as
neurotrophic factors. On the other hand, S1P has previously been
implicated in a number of pro-inflammatory processes. For
example, S1P induced an increase in expression levels of TNFa,
IL-1b, and iNOS and release of TNFa and NO by activated
microglia [6]. It was also shown to increase expression of pro-
inflammatory IL-8 and MCP-1 mRNA in human umbilical vein
endothelial cells through S1P1 and S1P3 [34].
In our study we found that MCP-1, RANTES and CXCL1 are
secreted by cultured primary rat astrocytes in response to S1P and
LPS, with CXCL1 showing the strongest induction. All three
factors are known to induce neutrophil and monocyte/macro-
phage recruitment into lesions, but only CXCL1 has been
described as having potential beneficial effects for oligodendro-
cytes. In LPS-activated astrocytes, S1P-induced CXCL1 release
was significantly increased compared to non-activated cells.
Furthermore we showed that a S1P3 agonist, which did not by
itself induce CXCL1 release in non-activated cells, significantly
induced release of this chemokine when cells were pre-activated
with LPS. This direct induction of the chemokine CXCL1 in
response to stimulation of S1P3 in LPS-activated astrocytes is
coherent with our observation showing a concomitant increase of
S1P3-mediated signaling in LPS-stimulated astrocytes. Further-
more, the S1P1 selective agonist AUY954, which did not increase
ERK-1/2 phosphorylation in LPS-stimulated astrocytes, also did
not induce CXCL1 release.
CXCL1 is described as a rat pro-inflammatory chemokine with
structural and functional homology to human interleukin-8 (IL-8)
[58]. It is expressed by inflammatory cells at sites of inflammation
and is involved in neutrophil and granulocyte infiltration into the
brain [59]. However, CXCL1 has also been shown to induce
proliferation of oligodendrocyte precursor cells both in vitro and in
vivo [60,61], and migration of these cells in vivo is arrested in its
presence [62]. Furthermore, mice that inducibly overexpress
CXCL1 under control of the astrocyte-specific gene GFAP
showed neuroprotection and remyelination in EAE [63]. The
same group also showed that CXCL1 was produced in MS tissues
by reactive astrocytes in close proximity to oligodendrocytes,
which express the CXCL1 receptor CXCR2 [64]. CXCL1 release
by activated astrocytes could thus act not only as a pro-
inflammatory chemokine, but could also exert beneficial effects
on remyelination in MS. Our data emphasize the role of S1P3
rather than S1P1 in increased CXCL1 release by activated
astrocytes, which probably involves ERK-1/2 signaling, as
suggested by previous studies that had shown the role of ERK-
1/2 in TLR-4 mediated release of IL-8 and MCP-1 in adipocytes
and in lung epithelial cells [65,66].
In summary, our study demonstrates that SphK1 and S1P3
expression, signaling and biological responses are increased in
LPS-activated astrocytes. Reactive astrocytes in MS lesions also
showed increased expression of SphK1 and S1P3, suggesting that
this signaling axis may play a role in mediating and amplifying
inflammatory responses in various CNS disorders in an autocrine/
paracrine fashion. Conversely, it may also lead to beneficial effects
on remyelination through release of CXCL1. How S1P3 signaling
in astrocytes induced by FTY720 could influence the disease
course in MS patients remains to be elucidated but inhibition of
SphK1/S1P3 signaling on astrocytes via inhibition of SphK1
activity could result in reduced neuroinflammation.
Materials and Methods
S1P3 expression in MS and control CNS tissues
Samples from cases clinically diagnosed as MS and confirmed
by neuropathological examination were provided by the NeuroR-
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Informed written consent from donors and/or their next of kin
was obtained for the donation of MS and normal control CNS
tissues to the NeuroResource tissue bank for research studies. The
NeuroResource tissue bank documentation for tissue donor
information and the consent forms for tissue donation were
approved by the Central London Research Ethics Committee 1,
London, U.K.. Permission was given by the NeuroResource MTA
Review Committee based at the UCL Institute of Neurology for
samples from the tissue bank to be used in this specific study. An
application for ethical permission to carry out this study on human
CNS tissues was approved by L’Association des Me ´decins du
canton de Gene `ve et Socie ´te ´M e ´dicale: Commission d’e ´thique
pour la Recherche Clinique en Ambulatoire, a Research Ethics
Committee based in Switzerland.
Cryostat sections (10 mm) were cut from 8 blocks of snap-frozen
MS lesions with adjacent tissue from the cerebrum of 7 MS
patients (average age 51 y (range 29–69 y); clinical disease
duration 21 y (range 8–34 y); interval between death and tissue
snap-freezing 15 h (range 8–24 h)). Sections were also cut from 5
blocks dissected from the cerebrum of 4 age-matched control cases
without CNS disease (average age 57 y (range 47–68 y); interval
between death and snap-freezing 19 h (range 11–23 h)). The tissue
blocks were dissected from periventricular or subcortical white
matter in frontal, parietal or occipital lobes and cerebellum. Anti-
myelin basic protein (MBP) (1:100; Cat. No. MAB382, Chemicon,
Temicula, CA) immunostaining of all MS lesions was performed to
assess demyelination (not shown). Oil red O and haematoxylin
histological screening (not shown) further demonstrated that 5
lesions were actively demyelinating, 1 was chronic-active and 2
were chronic-inactive.
For immunostaining sections were fixed (ice-cold acetone,
10 min), rinsed in phosphate-buffered saline (PBS) and blocked
in 10% normal goat serum and 1% bovine serum albumin (BSA;
low endotoxin, fatty acid free; Sigma, MO, USA) and incubated
(1 h, RT) with either a polyclonal anti-S1P3 antibody (1:100; Cat.
No. AB9289, Millipore, Temecula, CA) [30] or a polyclonal anti-
SphK1 antibody (1:50; Cat. No. AP7237c, Abgent Europe;
Oxfordshire, UK) [44]. Sections were then incubated with
biotinylated anti-rabbit antibody (1:500; 1 h, RT) and then for
1 h with A+B from a Vectastain ABC Kit (all from Vector
Laboratories Inc., California). Immunoreactivity was visualized by
NovaRed peroxidase substrate (Vector Laboratories), followed by
dehydration and cover-slipping with Eukitt
TM (Kindler GmbH &
Co, Freiburg, Germany). To identify cell types expressing S1P3
and SphK1 double-immunostainings were performed by incubat-
ing sections with mouse anti-GFAP (1:200; Chemicon, Temicula,
CA) or mouse anti-CD68 (1:250; Dako, Glostrup, Denmark) with
either anti-S1P3 or anti-SphK1 (1 h, RT) followed by goat anti-
rabbit coupled to Alexa 488 (1:200) for anti-S1P3 or SphK1 and
goat anti-mouse coupled to Alexa 555 (1:200; Invitrogen, Basel,
Switzerland) for anti-GFAP or anti-CD68. Sections were mounted
in FluorSave
TM (Calbiochem, San Diego, CA) and examined on a
Leica SP2 confocal microscope.
Animal studies
All the animal work was carried out after being approved by
the internal Merck Serono Ethical Committee and the cantonal
veterinarian office (license numbers 1040/3123/0-R and 1040/
3123/0-2R), as well as by the federal veterinarian office,
according to the Swiss Law and on Animal Protection (2008,
2009) and the Swiss ordinance on Animal Experimentation
(2010).
Rat astrocyte cultures
Glial cells were isolated from newborn OFA (Oncins France
Strain A) rat cortices essentially as described previously [67].
Briefly, brains were collected in dissection medium (HBSS,
penicillin/streptomycin, HEPES 10 mM, sodium bicarbonate
0.75% (all from GIBCO/Invtirogen). Cortices were cut into small
pieces and dissociated in 10 ml dissection medium containing
0.01% trypsin and 10 mg/ml DNAse I (Sigma; 10 min, 37uC).
Following centrifugation (1006 g, 5 min), the pellet was gently
dissociated and filtered through a 70 mm mesh, centrifuged and
resuspended in culture medium (Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen), 10% fetal bovine serum, penicillin/
streptomycin) and grown on poly-D-Lysine T75 flasks in a 10%
CO2 37uC incubator for 10 days with a medium change every 3–4
days. At confluence cells were submitted to two consecutive
shaking steps to remove microglia and oligodendrocyte progenitor
cells. The remaining astrocytes were washed with PBS and
detached with PBS-EDTA incubation followed by trypsin-EDTA
treatment, and plated according to experimental requirements.
Determination of mRNA levels by real-time PCR (qPCR)
For RNA isolation 3610
5 cells were grown in culture medium
for 2 days in six-well plates and then treated with 100 ng/ml LPS
(from Escherichia coli 0111:B4; Sigma) for 5 h. Total RNA was
isolated using a RNeasy microkit (Qiagen, Valencia, CA) and
reverse-transcribed using a iScript
TM cDNA Synthesis Kit (Bio-
Rad, Hercules, CA). Quantitative real time PCR was performed
using a SYBR green PCR kit (Roche, Basel, Switzerland) and
PCR products were detected using an ABI PRISM 7900 sequence
detection system (Applied Biosystems, Foster City, CA). Primers
used to amplify S1P1, S1P3, SphK1 and SphK2 were from Qiagen
(S1P1: QT00441007; S1P3: QT00440909; SphK1: QT00182035;
SphK2: QT01783145) and expression of these transcripts was
quantified against the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), which was amplified using
the primers 59-GGAGACAACTGGTCCTCCAGTG-39 and 59-
ACCTGCCAAGTATGATGACATCA-39. GAPDH expression
was used as a housekeeping gene as it was not modulated by the
treatment with LPS (data not shown). Expression levels of target
genes were analyzed using the SDS 2.2.2 software system (Applied
Biosystems, Foster City, CA).
Western blot analyses
To evaluate phosphorylated ERK-1/2 and phosphorylated Akt,
3610
5 cells in 6-well poly-D-lysine plates were grown for two days
in culture medium. They were then pretreated for 12 h with LPS
(100 ng/ml) in serum-free medium, followed by 20 min stimula-
tion with the S1P1 selective agonist AUY954 [68] or 10 mM of the
S1P3 selective agonist Compound 20 described by Schurer et al.
(2008) [32]. Compound 20 is a dicyclohexylamide and a
nanomolar selective S1P3 agonist with an EC50 value of
0.35 mM, and is inactive against S1P1, S1P2, S1P4 and S1P5.
Both compounds were synthesized as previously described [32,68].
Subsequently cells were lysed in 50 mM Tris/HCl buffer pH 8.0
containing 150 mM NaCl, 0.02% sodium azide, 0.1% SDS, 1%
IGEPAL Ca-630, 0.5% sodium deoxycholate, 40 mM b-glycero-
phosphate, 1% NaF, 0.1% sodium orthovanadate and protease
inhibitor mixture tablet (Roche). After a brief sonication protein
concentration was determined using a BCA kit (Pierce, Rockford,
IL) and 20 mg of protein in sample buffer containing DTT (Sigma)
was loaded on a SDS polyacrylamide gel (Invitrogen, NuPAGE
Novex Bis-Tris gels, 4–12%) for electrophoresis, and transferred to
a nitrocellulose membrane. Membranes were blocked using 5%
BSA/0.05% Tween-20H/PBS for incubation with polyclonal
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phorylated Akt (1:500; Cell Signaling Technology, Boston, MA),
or 5% non-fat dry milk/0.05% Tween-20H/PBS for a monoclonal
antibody against b-actin (1:5000; Millipore), for 1 h and then
probed with these antibodies overnight at 4uC. Immunoreactive
bands were detected with appropriate horseradish peroxidase-
conjugated secondary antibodies and an ECL detection kit (GE
Healthcare, Little Chalfont, U.K.).
An anti-SphK1 polyclonal antibody (Cell Signaling Technology,
Cat. No.:3297s; 1:700) [69] and a polyclonal anti-S1P3 antibody
(1:200; Cat. No.: 10006373, Cayman Chemicals, Tallinn, Estonia)
[70] were used to immunodetect SphK1 and S1P3 in membrane
fractions. Equal loading of protein was controlled by expression of
b-actin after membrane stripping.
Membrane fractionation
Cells were plated on 10 cm poly-D-lysine coated Petri dishes in
culture medium(2610
6cells/dish) untilthey reached90% confluence.
Serum was replaced 12 h before stimulation with LPS (100 ng/ml) for
the indicated time points. The reaction was terminated by washing the
cells twice in ice-cold PBS. Then the cells were scraped into ice-cold
PBS, centrifuged (5 min, 10006g), the supernatant was removed and
cells were triturated with a 25G needle in TBS (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl) and the lysate was centrifuged (30 min,
184,0006g). The supernatant was removed and membrane proteins
were solubilised by trituration with a 25G needle in TBS/1% Triton
X-100 containing EDTA-free protease inhibitor (Roche). The lysate
was incubated on ice for 15 min with repeated vortexing. Insoluble
debris was removed by centrifugation (10 min, 20,0006g,4 uC) and
supernatant protein concentrations were determined by BCA (Pierce).
Samples (20 mg) containing DTT and running buffer were heated
(60uC, 3 min) and loaded on a 10% SDS-page gel for electrophoresis
and Western blot analysis.
SphK1 activity assay by thin layer chromatography
SphK1 activity was measured according to Olivera [71] with a
few modifications. Briefly, cells were plated on 10 cm poly-D-
lysine coated Petri dishes in culture medium (2610
6 cells/dish)
until they reached 90% confluence. Serum was replaced 12 h
before stimulation and the cells than pre-incubated or not for
2 hours with 10 mg/ml of the SphK inhibitor (SKI; (2-(p-
Hydroxyanilino)-4-(p-chlorophenyl)) thiazole HCl (Merck Biosci-
ence, Darmstadt, Germany), followed by stimulation with 500 ng/
ml LPS for 45 min. The reaction was then stopped on ice and the
cells were scraped from the dishes using 20 mM Tris-HCl, buffer
pH 7.4, containing 10% glycerol, 1 mM 2-mercapoethanol,
1 mM EDTA, 1 mM sodium orthovanadate, 40 mM b-glycero-
phosphate, 0.5 mM 4-deoxypyridoxine, 15 mM NaF, 0.1%
Triton X-100 and EDTA-free protease inhibitor mixture (Roche).
After brief sonication and determination of protein concentration,
100 mg of protein was incubated in 200 ml final volume of reaction
mixture containing 50 mM sphingosine (Avanti Polar Lipids,
Alabaster, AL) in 5% Triton X-100, [c-
32P]ATP (Perkin-Elmer
Life and Analytical Sciences; 10 mCi, 20 mM in 200 mM MgCl2)
and SphK1 activity assay buffer for 37uC. The reaction was
terminated by addition of 20 ml 1 M HCl followed by 400 mlo f
chloroform:methanol:HCl (100:200:1, v/v/v) and allowed to stand
at room temperature for 10 min, then 125 ml chloroform and
125 ml 2 N KCl were added. Samples were centrifuged (4006g,
5–10 min) and the organic phase was dried under a nitrogen
stream. The pellet was dissolved in 50 ml of chloroform:metha-
nol:HCl (100:100:1, v/v/v) and spotted onto a silicon TLC plate
which was placed in a TLC developing tank (1-butanol:methano-
l:acetic acid:water (80:20:10:20, v/v)). S1P radioactive spots were
exposed to X-ray film, developed with a Phosphoimager
TM and
analyzed using Quantity OneH software.
Proliferation Assay
To study the proliferation of astrocytes in response to S1P or
LPS, 5000 cells/well were plated in 96-well poly-D-lysine plates
over night in culture medium. At this density, cells are not
confluent. The next day, they were washed in serum-free medium
and then incubated with increasing concentrations of S1P (10,
100, 1000 nM) or LPS (1, 10, 100 ng/ml) in fresh serum-free
medium for 24 h. During the last 18 h [
3H]-thymidine (1 mCi/ml)
was added to the wells. The cells were then harvested using a
Filtermate Harvester (Packard) and [
3H]-thymidine uptake was
counted using a Microbeta Trilux counter (Perkin Elmer).
Scratch migration assay
Astrocytes were plated onto 24-well poly-D-lysine plates
(3610
5cells/well) and incubated overnight in 10% CO2 at 37uC.
The following day one scratch per wellwas made using a 1 mlpipette
tip, and cells were washed twice in PBS to remove debris. Cells were
treated with the different stimuli in DMEM 1.5% horse serum and
allowed to migrate into the scratch for 48 h. Treatments were
repeated 24 h later without changing the medium. For inhibition
studies, cells were pre-incubated with 10 mg/ml SKI (Merck
Bioscience, Darmstadt, Germany) for 1 h before performing
scratches. After the scratch, the cells were then treated with a single
dose of LPS and allowed to migrate for 48 h. To investigate the
influence of proliferation on astrocyte migration the antimitotic agent
Cytosine b-D-arabinofuranoside hydrochloride (10 mM; Cat. No. C-
6645; Sigma) was applied together with LPS (100 ng/ml) or S1P
(500 nM). After 48 h, the cells were fixed with 4% paraformalde-
hyde, washed and permeabilized with 20% methanol and then with
0.5% Tween 20H. Following washing they were incubated with
rabbit anti-GFAP antibody (1:200; Cat. No. Z0334, DAKO) for 1
day at 4uC and then incubated with a goat anti-rabbit Alexa 555
1:250 (Invitrogen) and Hoechst1:10,000 (Sigma) in PBS for 1 h. Cells
were washed and four photographs per scratch were taken with a
fluorescence microscope in a blinded fashion. The percentage of cells
which migrated into a scratch was determined by analyzing the
percentage of area positive for GFAP using ImageJ software.
CXCL1 protein determination
CXCL1 protein, also called GRO (Growth regulated oncogene)
or CINC-1 (Cytokine induced neutrophil chemoattractant-1),
secreted by astrocytes was measured using a rat CXCL1 ELISA kit
(GRO/CINC-1C ELISA Kit, R&D Systems) following manufac-
turer’s instructions. Astrocytes were plated onto 96-well poly-D-
lysine plates (2610
4 cells/well) for one day then the culture
medium was replaced by serum-free medium containing LPS
(100 ng/ml) for 12 h. The next day cells were treated with a S1P3
selective agonist (Compound 20, 10 mM), S1P (1 mM; Avanti Polar
Lipids) or the S1P1 selective agonist AUY954 (10 mM) for 5 h, and
culture medium was collected and analyzed by ELISA.
Data plotting and statistical analyses
All data were plotted using GraphPad Prism version 5.02
(GraphPad Software, San Diego California USA). One-way
ANOVA was applied to evaluate statistical significances. Post-
tests and significances are described in the Figure Legends.
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